UnknownNot Applicable

An Integrative-"Omics" Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China

China2,000 participantsStarted 2015-07-01

Plain-language summary

This is a multi-omics research of Chinese cardiomyopathies patients, aiming to determine genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Subjects who was diagnosed as cardiomyopathy by medical history, clinical symptoms, laboratory tests including ECG, echocardiography.
✓. Subject understands study requirements aand agrees to sign an informed consent form prior to any study procedures.

Exclusion criteria

✕. Endocrine disease known to cause heart muscle disease (including infants of diabetic mothers)
✕. History of rheumatic fever
✕. Toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal radiation, iron overload or heavy metal exposure)
✕. HIV infection or born to an HIV positive mother
✕. Kawasaki disease
✕. Immunologic disease
✕. Uremia, active or chronic
✕. Abnormal ventricular size or function that can be attributed to intense 9.physical training or chronic anemia

What they're measuring

The primary objective of this study is to determine whether variation in genetic background or differentially expressed molecules influences clinical outcomes in cardiomyopathy.

Timeframe: Five year

Trial details

NCT IDNCT03076580

SponsorBeijing Institute of Heart, Lung and Blood Vessel Diseases

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2018-07-01

Contact for this trial

Jie Du, PhD

jiedubj@126.com

View on ClinicalTrials.gov More Dilated Cardiomyopathy trials